Involving Proteinase Patents (Class 435/23)
  • Classifying Skin Lesions Using Mass Spectrometry Proteomic Approach
    Publication number: 20140044673
    Abstract: The present invention provides for a mass spectrometry proteomic approach to distinguishing Spitz nevi from Spitzoid malignant melanoma. Histology directed mass spectral profiling allows for targeted analysis of sites of melanocytic lesion within formalin-fixed, paraffin embedded excisional biopsies. The classification system identified 5 peptide peaks, of which two have been identified as originating from vimentin and actin. A sensitivity and specificity for Spitz nevi of 97% and 90%, respectively, were achieved.
    Type: Application
    Filed: February 1, 2013
    Publication date: February 13, 2014
    Applicant: VANDERBILT UNIVERSITY
    Inventor: VANDERBILT UNIVERSITY
  • WOUND PROGNOSIS
    Publication number: 20140045761
    Abstract: Methods and devices for determining the healing status of wounds, in particular of chronic wounds are provided. Also provided are kits comprising the diagnostic devices, and methods of wound diagnosis and treatment using the diagnostic devices and methods. A diagnostic apparatus (device) for monitoring wounds that exude a wound fluid and determining whether said wounds would be responsive to treatment with wound therapy such as oxidized cellulose therapy is also provided along with kits comprising the diagnostic apparatus and a wound dressing. Furthermore, methods of prognosing and treating wounds that exude a wound fluid are also provided.
    Type: Application
    Filed: January 31, 2012
    Publication date: February 13, 2014
    Applicant: Systagenix Wound Management IP CO. BV
    Inventor: Molly Gibson
  • EVALUATION OF COPOLYMER DIETHYLAMIDE
    Publication number: 20140045204
    Abstract: Methods of analyzing glatiramer acetate (GA) or a polymeric precursor thereof are provided. The methods can include determining a level of one or more diethylamide-modified amino acids in a sample comprising GA or a polymeric precursor thereof, and selecting at least a portion of the sample based on the assessment of the one or more diethylamide-modified amino acids in the sample.
    Type: Application
    Filed: September 6, 2013
    Publication date: February 13, 2014
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Cuihua Liu, Shiming Dong, Xiao-Jin Xu, Jonathan C. Lansing, Yanjie Jiang
  • METHOD AND APPARATUS FOR PERFORMING RETENTION TIME MATCHING
    Publication number: 20140038216
    Abstract: A method for matching a precursor ion with one or more related product ions includes providing input data sets obtained from sample injections, each of the data sets including a precursor ion and one or more product ions, normalizing the input data sets in accordance with a single retention time for the precursor ion, determining which product ions are within a predetermined retention time window with respect to the single retention time, and, if a product ion is within the predetermined retention time window for a specified number of the input data sets, determining that the product ion is related to the precursor having the single retention time. An apparatus for analyzing a sample includes a chromatography module, a mass-spectrometry module in communication with the chromatography module, and control unit in communication with the chromatography module and the mass-spectrometry module.
    Type: Application
    Filed: April 15, 2013
    Publication date: February 6, 2014
    Applicant: Waters Technologies Corporation
    Inventor: Waters Technologies Corporation
  • METHOD AND APPARATUS FOR FRACTIONATION-BASED CHEMICAL ANALYSES
    Publication number: 20140038217
    Abstract: A method (100) for analyzing chemicals includes fractionating a complex sample into at least two sample portions that each includes potions of two polypeptides though in different concentration ratios, digesting and performing LC/MS on each of the sample portions (110, and associating precursor ions observed via LC/MS with their corresponding polypeptide in response to LC/MS provided intensity data (170). A set of precursor ions that has substantially similar intensity ratios in both sample portions is determined to be associated with the same polypeptide.
    Type: Application
    Filed: April 16, 2013
    Publication date: February 6, 2014
    Applicant: Waters Technologies Corporation
    Inventor: Waters Technologies Corporation
  • NOVEL BIOMARKERS FOR DETECTING NEURONAL LOSS
    Publication number: 20140038834
    Abstract: The present invention relates to a biomarker for the detection of brain damage or a disease associated with loss of neurons, said biomarker comprising a protein fragment of the neurofilament heavy chain (NfH) protein in a biological sample, wherein said protein fragment is a polypeptide selected from the group consisting of i) a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and polypeptides composed of amino acids 476-1026 and 476-986 of SEQ ID NO 6; ii) a protein fragment of the NfH protein having an amino acid sequence that is at least 60% identical to SEQ ID NO:1, at least 60% identical to SEQ ID NO:2, at least 60% identical to SEQ ID NO:3, at least 60% identical to SEQ ID NO:4, at least 60% identical to SEQ ID NO:5; or at least 60% identical to a polypeptide composed of amino acids 476-1026 and.
    Type: Application
    Filed: July 7, 2011
    Publication date: February 6, 2014
    Applicant: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG
    Inventor: Axel Franz Siegfried Petzold
  • Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity
    Publication number: 20140037661
    Abstract: The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. Furthermore, the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy.
    Type: Application
    Filed: February 8, 2012
    Publication date: February 6, 2014
    Applicant: PHADIA AB
    Inventors: Alexandra Baar, Rudolf Valenta, Sandra Pahr, Bharani Srinivasan, Susanne Vrtala
  • PROTEOLYSIS DETECTION
    Publication number: 20140038218
    Abstract: Disclosed are electrochemical methods, apparatus, systems and kits for the detection or monitoring of proteolysis of proteinaceous matrices such as fibrin clots. The methods, apparatus, systems and kits generally include the use of voltammetric techniques to measure the changes in current that result from diffusion of an electroactive species towards an electrode on proteolysis of a proteinaceous matrix.
    Type: Application
    Filed: December 22, 2011
    Publication date: February 6, 2014
    Applicant: The University of Queensland
    Inventor: Krassen Dimitrov
  • METHOD FOR SCREENING INHIBITORY SUBSTANCES TO INFLAMMATORY SKIN-AGING
    Publication number: 20140038220
    Abstract: Disclosed is a method for screening a substance inhibiting inflammatory skin aging, comprising: treating an immune cell with an inflammatory stimulant; treating a skin cell with a candidate substance; treating the skin cell treated with the candidate substance, with the immune cell treated with the inflammatory stimulant; and measuring the concentration of matrix metalloproteinase-1 (MMP-1) in the skin cell treated with the immune cell.
    Type: Application
    Filed: April 13, 2012
    Publication date: February 6, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Ji Seong Kim, Jin Young Lee, Jun Seong Park, Hyang Tae Choi, Han Byul Kim, Ji Hyun Bae
  • METHODS FOR DETECTING OR PREDICTING KIDNEY DISEASE
    Publication number: 20140038203
    Abstract: Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.
    Type: Application
    Filed: July 9, 2013
    Publication date: February 6, 2014
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: John ARTHUR, Michael JANECH, Joseph ALGE
  • THYROGLOBULIN QUANTITATION BY MASS SPECTROMETRY
    Publication number: 20140038219
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Application
    Filed: October 14, 2013
    Publication date: February 6, 2014
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: YANNI ZHANG, NIGEL J. CLARKE, RICHARD E. REITZ
  • BIOMARKERS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Publication number: 20140030735
    Abstract: The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.
    Type: Application
    Filed: March 7, 2012
    Publication date: January 30, 2014
    Applicant: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Salim Merali, Steven G. Kelsen, Carlos A. Barrero
  • METHODS OF DETECTING THERAPEUTIC EXOSOMES
    Publication number: 20140031256
    Abstract: We describe a method of detecting a therapeutic exosome, the method comprising detecting an activity of an exosome. The activity may be selected from the group consisting of: (a) immunodulatory activity; (b) complement inhibition activity; (c) proteasome activity; (d) glycolytic enzyme activity; (e) anti-oxidative activity; (f) extracellular matrix (ECM) modifying activity; (g) NT5E (CD73) ecto-5?-ectonucleotidase activity; (h) ion homeostasis activity; and (i) chaperone activity. If the exosome is detected as having one or more such activities, the exosome is likely to comprise a therapeutic exosome having therapeutic activity.
    Type: Application
    Filed: February 10, 2012
    Publication date: January 30, 2014
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sai Kiang Lim
  • Devices and Methods for the Fast Photochemical Oxidation of Proteins
    Publication number: 20140030751
    Abstract: Embodiments of the present disclosure provide for devices and methods that can be used in a process for the fast photochemical oxidation of proteins, and the like.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 30, 2014
    Inventor: Joshua S. Sharp
  • METHOD AND REAGENTS FOR TREATING HEPATIC FIBROSIS AND INFLAMMATION
    Publication number: 20140024038
    Abstract: The invention relates to methods for identifying an anti-fibrotic or anti-inflammatory agent comprising determining cathepsin S expression in activated hepatic stellate cells which have been exposed to a test compound and comparing expression to non-exposed hepatic stellate cells. The invention also relates to methods for treating a disorder characterised or caused by hepatic fibrosis or inflammation, comprising administering a cathepsin S inhibitor to a subject.
    Type: Application
    Filed: July 23, 2013
    Publication date: January 23, 2014
    Inventors: Gunter Maubach, Lang Zhuo, Michelle Chin Chia Lim
  • METHODS AND COMPOUNDS FOR INCREASING SENSITIVITY OF BOTULINUM ASSAYS
    Publication number: 20140024063
    Abstract: Apparatus, systems and methods can provide improved detection of botulinum neurotoxins. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Förster resonance energy transfer (FRET) and non-FRET cell-based assays. In another aspect, non-FRET assays and constructs utilize a reporter that is not coupled with the second fluorophore in a manner that produces significant FRET. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 23, 2014
    Inventors: Timothy M. Piazza, Ward C. Tucker
  • Methods for assaying enzyme activities
    Patent number: 8632992
    Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: January 21, 2014
    Assignee: Promega Corporation
    Inventors: Thomas Kirkland, Andrew L. Niles, Carolyn Woodroofe Hitko
  • Method for grass species identification
    Patent number: 8632993
    Abstract: The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: January 21, 2014
    Assignee: Stallergenes S.A.
    Inventors: Philippe Moingeon, Thierry Batard, Emmanuel Nony
  • PROTEOLYTIC DIGESTION KIT WITH DRIED REAGENTS
    Publication number: 20140017716
    Abstract: Compositions and methods are provided for the rapid and efficient denaturation and degradation of protein samples. The compositions and methods produce samples that can readily be analyzed by, for example, mass spectrometry. Unwanted dilution of the sample is avoided and the samples and methods are amenable for use with robotic laboratory sample handling instruments. The compositions and methods surprisingly provide significantly improved reproducibility and accuracy of the resulting mass spectrometric analyses.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 16, 2014
    Inventor: N. Leigh ANDERSON
  • METALLOPROTEINASE-9 OLIGOPEPTIDES AND THEIR THERAPEUTIC USE
    Publication number: 20140017225
    Abstract: The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides, SEQ ID wherein the matrix metalloproteinase oligopeptide is at least one of SEQ ID 7, 11, 12, 18 and 19 and combination thereof. These oligopeptides are bound to antibodies to create an immune response in the subject mammal against the matrix metalloproteinases of various diseases. The instance method is a means of therapeutic intervention against the disease spread created by the matrix metalloproteinases. Further use of these oligopeptide-antibody responses can be extended to any and all diseases that use the matrix metalloproteinases to aid in their pathogenicity.
    Type: Application
    Filed: April 10, 2013
    Publication date: January 16, 2014
    Inventor: MATTHIAS W. RATH
  • TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA
    Publication number: 20140018431
    Abstract: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 16, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Michael Wade, Stuart Rich, Eugene Sullivan, Robert Roscigno, Roger Jeffs
  • Chemically patterned hydrogels, manufacture and use thereof
    Patent number: 8629197
    Abstract: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: January 14, 2014
    Inventors: Molly Shoichet, Jordan Wosnick, Ryan Wylie
  • Methods and compositions for multiplexed screening of disease
    Patent number: 8628936
    Abstract: The invention relates to a method for aiding the diagnosis of a disorder in a subject, said method comprising; providing a sample from said subject wherein the sample comprises blood; assaying at least two characteristics of said sample, said characteristics selected from: the structural composition of a polypeptide comprised by said sample; a metabolite comprised by said sample; and a catalytic activity comprised by said sample, wherein each of said at least two characteristics is determined from a multiplexed analysis of the same sample. The invention also relates to certain compositions.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 14, 2014
    Assignees: King's College London, Guy's and St. Thomas' NHS Foundation Trust
    Inventors: Charles Turner, Raymond Neil Dalton
  • ACTIVATABLE FLUOROGENIC COMPOUNDS AND USES THEREOF AS NEAR INFRARED PROBES
    Publication number: 20140010763
    Abstract: Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes.
    Type: Application
    Filed: September 15, 2013
    Publication date: January 9, 2014
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Doron SHABAT, Ronit Satchi-Fainaro
  • CASPASE INHIBITORS AND USES THEREOF
    Publication number: 20140011847
    Abstract: This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.
    Type: Application
    Filed: August 15, 2013
    Publication date: January 9, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Lisa M. ELLERBY, Jonathan A. ELLMAN, Melissa J. LEYVA
  • DETECTION OF PROTEASE AND PROTEASE ACTIVITY USING A SINGLE NANOCRESCENT SERS PROBE
    Publication number: 20140011705
    Abstract: This invention pertains to the in vitro detection of proteases using a single peptide-conjugate nanocrescent surface enhanced Raman scattering (SERS) probes with at least nanomolar sensitivity. The probe enables detection of proteolytic activity in extremely small volume and at low concentration. In certain embodiments the probes comprise an indicator for the detection of an active protease, where the indicator comprises a nanocrescent attached to a peptide, where said peptide comprises a recognition site for the protease and a Raman tag attached to the peptide.
    Type: Application
    Filed: January 28, 2013
    Publication date: January 9, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
  • Diagnostic assay for spongiform encephalopathies
    Patent number: 8623605
    Abstract: The invention provides a method of diagnosis of a spongiform encephalopathy in a diagnostic sample of a valid body tissue taken from a subject, which comprises detecting an increased proteolytic activity in the diagnostic sample, compared with a sample from a control subject.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: January 7, 2014
    Assignee: Electrophoretics Limited
    Inventors: Ian Hugo Pike, Malcolm Andrew Ward, Darragh Patrick William O'Brien
  • Method for Enzymatic Treatment of Tissue Products
    Publication number: 20140004549
    Abstract: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix.
    Type: Application
    Filed: September 5, 2013
    Publication date: January 2, 2014
    Inventors: Yi Chen, Hui Xu, Li Ting Huang, Wenquan Sun
  • CMET PROTEIN SRM/MRM ASSAY
    Publication number: 20140005282
    Abstract: Specific peptides are provided, and derived ionization characteristics of those peptides, from the Hepatocyte Growth Factor Receptor (cMET) protein. The peptides are particularly and surprisingly advantageous for quantifying by the method of Selected Reaction Monitoring (SRM) mass spectrometry the cMET protein directly in biological samples that have been fixed in formalin, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including: formalin-fixed tissue/cells; formalin-fixed/paraffin embedded (FFPE) tissue/cells; FFPE tissue blocks and cells from those blocks; and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: December 27, 2011
    Publication date: January 2, 2014
    Applicant: EXPRESSION PATHOLOGY, INC.
    Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
  • METHOD FOR THE DETERMINATION OF BOTULINUM NEUROTOXIN BIOLOGICAL ACTIVITY
    Publication number: 20140004541
    Abstract: The present invention relates to means and methods for determining neurotoxin activity. Specifically, it relates to a polypeptide having caspase activity comprising a large subunit and a small subunit wherein the caspase further comprises a neurotoxin cleavage site which upon cleavage activates the caspase activity. Also encompassed are polynucleotides encoding the polypeptides as well as vectors or host cells comprising the polynucleotides. The present invention further relates to a method for determining neurotoxin activity in a sample based on the polypeptide of the invention as well as the use of the polypeptide for determining neurotoxin activity in a sample, in general.
    Type: Application
    Filed: March 9, 2012
    Publication date: January 2, 2014
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Klaus Fink, Martin Vey
  • Early detection of pathogens in blood
    Patent number: 8617839
    Abstract: The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na3PO4.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: December 31, 2013
    Assignee: University of South Florida
    Inventor: Matt Ewert
  • AGENT FOR SEARCHING FOR PROTEIN CRYSTALLIZATION CONDITIONS AND METHOD OF SEARCHING FOR PROTEIN CRYSTALLIZATION CONDITIONS
    Publication number: 20130344523
    Abstract: An agent for searching for protein crystallization conditions, containing a water-swellable layered silicate having a fluorine atom and a hydroxyl group, wherein the fluorine atom is covalently bonded to the silicate by isomorphous substitution with the hydroxyl group. A method of searching for protein crystallization conditions, which comprises a step of mixing the agent for searching for protein crystallization conditions described above and a solution in which a protein is dissolved.
    Type: Application
    Filed: March 29, 2012
    Publication date: December 26, 2013
    Applicants: TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION, KUNIMINE INDUSTRIES CO., LTD.
    Inventors: Keiichi Kurosaka, Munehiro Kubota, Kengo Sakaguchi, Keita Ino, Itsumi Udagawa, Kazuki Iwabata, Yoichi Takakusagi, Yasutaka Seki
  • Methods for Improving Diabetes Management
    Publication number: 20130345175
    Abstract: A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include N?-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and N?-carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes related kidney disease and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 26, 2013
    Inventor: Paul J. Beisswenger
  • ANALYSIS METHOD
    Publication number: 20130344524
    Abstract: In a method for detecting a glucagon-secretin family peptide in a sample, the sample is contacted with a cleaving agent capable of digesting the glucagon-secretin family peptide by cleaving a peptide bond of at least one aspartic acid within the glucagon-secretin family peptide and thereby generating a plurality of peptide fragments, at least one of the peptide fragments containing an N-terminal end of the glucagon-secretin family peptide. The peptide fragment that contains the N-terminal end of the glucagon-secretin family peptide is then detected using liquid chromatography and mass spectrometry. The amount of peptide fragment that contains the N-terminal end of the glucagon-secretin family peptide in the sample can then be quantitated using a calibration curve.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.
    Inventors: Atsushi Miyachi, Yoshika Yasuda, Hiroko Hirooka
  • ANTIMICROBIAL AGENTS
    Publication number: 20130344055
    Abstract: The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive.
    Type: Application
    Filed: December 23, 2011
    Publication date: December 26, 2013
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, LYSANDO AG
    Inventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
  • Method for treating pervasive development disorders
    Patent number: 8613918
    Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: December 24, 2013
    Assignee: Curemark LLC
    Inventor: Joan M. Fallon
  • USE OF IDE AS A BIOMARKER FOR A SCALP CONDITION
    Publication number: 20130337085
    Abstract: The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff condition of the scalp.
    Type: Application
    Filed: December 12, 2011
    Publication date: December 19, 2013
    Applicant: L'oreal
    Inventors: Caroline Delattre, Philemon Sirven, Dominique Bernard
  • METHOD OF PREDICTING ACUTE APPENDICITIS
    Publication number: 20130338243
    Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
    Type: Application
    Filed: August 9, 2013
    Publication date: December 19, 2013
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Alex Kentsis, Hanno Steen, Richard Bachur
  • METHOD FOR DETECTING A WOUND INFECTION
    Publication number: 20130337484
    Abstract: The present invention relates to a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.
    Type: Application
    Filed: July 16, 2013
    Publication date: December 19, 2013
    Inventor: Eva Wehrschütz-Sigl
  • Compounds and methods for identifying compounds which inhibit a new class of aspartyl proteases
    Patent number: 8609087
    Abstract: Compounds and methods for designing and identifying compounds which inhibit TFPP-like aspartyl protease enzymes by targeting the aspartic acid residues of the active site or mimicking peptides corresponding to the region surrounding the substrate's cleavage site are provided. Agents identified as inhibitors of TFPP-like aspartyl proteases such as type 4 prepilin peptidases are expected to be useful as anti-bacterial agents and in inhibiting development of drug resistant strains of bacteria.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: December 17, 2013
    Assignee: Trustees of Dartmouth College
    Inventors: Ronald K. Taylor, Christian F. LaPointe
  • Methods, peptides and biosensors useful for detecting a broad spectrum of bacteria
    Patent number: 8609358
    Abstract: Described herein are methods of detecting a wound infection and for detecting the presence or absence of bacteria, for example, wound bacteria in a sample, by contacting a sample with a peptide substrate derived from the modification of the reactive site loop (RSL) domain of the ? 1-proteinase inhibitor. In the current invention, we have demonstrated that these peptide substrates without the alpha 1 protein can be efficiently used as peptide substrates. The modification or the absence of modification of this peptide substrate by the enzyme produced and/or secreted by the bacteria, can serve as an indicator for the presence or absence of the bacteria in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: December 17, 2013
    Assignee: Systagenix Wound Management (US), Inc.
    Inventors: Shite Sebastian, Gerard J. Colpas, Diane L. Ellis-Busby, Jennifer M. Havard, Mitchell C. Sanders
  • METHOD FOR USING AN ENZYME RESISTANT TO HIGH PRESSURES
    Publication number: 20130330758
    Abstract: At least at least one embodiment of the present invention relates to a method for using a high pressure-resistant enzyme in a high pressure condition; a method for promoting the activity of the high pressure-resistant enzyme by means of a high pressure treatment; a composition, which contains the high pressure-resistant enzyme, for decomposing proteins under a high pressure condition; a composition, which contains the composition for decomposing proteins, for preparing natural flavoring substances; a container for high pressure treatment, which contains the composition for decomposing proteins; and a method for measuring the activity of the high pressure-resistant enzyme, which comprises a step of decomposing an azocasein solution serving as a substrate by using the high pressure-resistant enzyme treated under a high pressure condition.
    Type: Application
    Filed: February 20, 2012
    Publication date: December 12, 2013
    Applicant: KOREA FOOD RESEARCH INSTITUTE
    Inventors: Nam-Soo Kim, Chong-Tai Kim, Yong-Jin Cho, Chul-Jin Kim, Jin-Soo Maeng, Soo-Jin Kwon
  • NITRATED CARDIAC TROPONIN I AS A BIOMARKER OF CARDIAC ISCHEMIA
    Publication number: 20130330744
    Abstract: The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. Diagnosis and prognosis is conducted by determining the amount of nitrated cardiac troponin I in serum samples of subjects and the ratio of nitrated cardiac troponin I to non-nitrated cardiac troponin I in serum samples of subjects. This biomarker can be detected by immunoassay techniques and tandem mass spectrometry. The present invention further relates to peptides, antibodies, compositions, methods, techniques, tests and kits for the identification and quantification of nitrated cardiac troponin I in samples of subjects.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 12, 2013
    Inventors: Gabriela Venturini Da Silva, Alexandre Da Costa Pereira, José Eduardo Krieger, Deborah Schetchman, Pedro Lemos, Jeane Mike Tsutsui, Valdemir Melechco Carvalho, Karina Helena Morais Cardozo
  • ENHANCING ENDOTOXIN DETECTION
    Publication number: 20130330759
    Abstract: Provided herein are methods for detecting endotoxin or Gram negative bacteria in a sample. Kits for detecting endotoxin or Gram negative bacteria in a sample are provided.
    Type: Application
    Filed: February 28, 2012
    Publication date: December 12, 2013
    Applicant: BIODTECH, INC.
    Inventors: Michael G. Pepe, Milton Keith Champion
  • CRYSTAL STRUCTURE AND PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE
    Publication number: 20130330358
    Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 12, 2013
    Inventors: Jae Jung, Hye-Ra Lee, Myung Hee Kim, Tae-Kwang Oh, Jung-Won Hwang
  • Luciferase-based assays
    Patent number: 8603767
    Abstract: A method and kit are provided for enhancing the tolerance of an assay reagent to compounds in an assay sample, the assay reagent including a luciferase enzyme. The method includes contacting the luciferase with a tolerance enhancement agent in an amount sufficient to substantially protect luciferase enzyme activity from interference of the compound and minimize interference by at least about 10% relative to an assay not having tolerance enhancement agent.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 10, 2013
    Assignee: Promega Corporation
    Inventors: Erika Hawkins, James J. Cali, Samuel Kin Sang Ho, Martha A. O'Brien, Richard Somberg, Robert F. Bulleit, Keith V. Wood
  • Enzymatic preparation of plant fibers
    Patent number: 8603802
    Abstract: A method of extracting fibers from decorticated plant bast skin involves pre-treating decorticated plant bast skin of a fiber plant with an aqueous solution containing trisodium citrate having a pH in a range of about 8-14 at a temperature of about 90° C. or less; and subsequently treating recovered fibers with a protease at alkaline pH.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: December 10, 2013
    Assignee: National Research Council of Canada
    Inventors: Wing L. Sung, Mark Wood, Fang Huang
  • COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF
    Publication number: 20130323771
    Abstract: The present invention relates to analytical methods such as molecular weight determination of polypeptide, in particular Glatiramer acetate. The present invention further relates to an improved process for preparation of polypeptides or pharmaceutically acceptable salts thereof, particularly Glatiramer acetate also known as Copolymer-1. The present invention further relates to characterization of Glatiramer acetate by peptide mapping.
    Type: Application
    Filed: February 14, 2012
    Publication date: December 5, 2013
    Applicant: USV LIMITED
    Inventors: Dhananjay Govind Sathe, Avinash Venkatraman Naidu, Sundaram Subramanian, Anindya Sibnath Bhattacharyya, Rakesh Shekhawat, Divya Lal Saksena, Ramanujam Sukumar, Sanjay Vyankatrao Patil
  • Process controls for molecular assay
    Patent number: 8597884
    Abstract: A full process control for use with a molecular assay and a method of determine the efficacy of the molecular assay. A full process control can include a fixed cell, and specifically can include a fixed vegetative cell. A method of determining the efficacy of a molecular assay can include providing an internal control, mixing the internal control with a sample, lysing the internal control and the sample, and detecting the lysis product. The full process control and/or the internal control can be Bacillus subtilis cells.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: December 3, 2013
    Assignee: Becton, Dickinson and Company
    Inventors: Benoit Dore, Christian Menard, Tobin Hellyer
  • Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition
    Patent number: 8597904
    Abstract: The invention disclosed herein generally relates to methods and compositions for inhibiting proteasome activity comprising a syrbactin compound have the structure of Formula (I) or (II).
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 3, 2013
    Assignee: Pono Corporation
    Inventors: Andre S. Bachmann, Robert Dudler, Michael Groll